Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

1.2K
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

783
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
783
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

482
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
482
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

1.8K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Three-year functional, physical, and mental health outcomes after critical COVID-19: A prospective multicentre cohort study.

PloS one·2026
Same author

Long-Term Outcomes and Recovery Trajectories in Out-of-Hospital Cardiac Arrest: A 2-Year Follow-Up of the Randomized Clinical TTM2 Trial.

JAMA neurology·2026
Same author

Aetiology and impact of bacterial bloodstream infections in mechanically ventilated COVID-19 patients: A prospective Swedish multicenter cohort study.

PloS one·2026
Same author

Blood biomarkers for the prediction of outcome after cardiac arrest: an international prospective observational study within the Targeted Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest (TTM2) trial.

The Lancet. Respiratory medicine·2025
Same author

Impact of frailty on mortality, functional outcome, and health status after out-of-hospital cardiac arrest: insights from the TTM2-trial.

Intensive care medicine·2025

Related Experiment Video

Updated: Apr 17, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

6.0K

The inflammatory marker suPAR after cardiac arrest.

Malin Rundgren1, Stig Lyngbaek2, Helle Fisker3

  • 11 Department of Clinical Sciences, Anaesthesia and Intensive Care, Skane University Hospital, Lund University , Lund, Sweden .

Therapeutic Hypothermia and Temperature Management
|February 20, 2015
PubMed
Summary

Soluble urokinase plasminogen activator receptor (suPAR) levels were higher in non-survivors of cardiac arrest (CA) within 36 hours. However, suPAR levels showed substantial overlap, limiting their prognostic value for CA outcomes.

More Related Videos

Standardized Model of Ventricular Fibrillation and Advanced Cardiac Life Support in Swine
05:36

Standardized Model of Ventricular Fibrillation and Advanced Cardiac Life Support in Swine

Published on: January 30, 2020

8.7K
Normothermic Cardiac Arrest and Cardiopulmonary Resuscitation: A Mouse Model of Ischemia-Reperfusion Injury
10:25

Normothermic Cardiac Arrest and Cardiopulmonary Resuscitation: A Mouse Model of Ischemia-Reperfusion Injury

Published on: August 30, 2011

18.9K

Related Experiment Videos

Last Updated: Apr 17, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

6.0K
Standardized Model of Ventricular Fibrillation and Advanced Cardiac Life Support in Swine
05:36

Standardized Model of Ventricular Fibrillation and Advanced Cardiac Life Support in Swine

Published on: January 30, 2020

8.7K
Normothermic Cardiac Arrest and Cardiopulmonary Resuscitation: A Mouse Model of Ischemia-Reperfusion Injury
10:25

Normothermic Cardiac Arrest and Cardiopulmonary Resuscitation: A Mouse Model of Ischemia-Reperfusion Injury

Published on: August 30, 2011

18.9K

Area of Science:

  • Cardiology
  • Intensive Care Medicine
  • Biomarker Research

Background:

  • Soluble urokinase plasminogen activator receptor (suPAR) is an inflammatory marker.
  • Cardiac arrest (CA) and resuscitation induce significant inflammatory responses.
  • suPAR's role in predicting outcomes after CA and hypothermia is not fully understood.

Purpose of the Study:

  • To investigate soluble urokinase plasminogen activator receptor (suPAR) levels in patients following cardiac arrest (CA).
  • To assess the relationship between suPAR levels and patient outcomes, including survival after 6 months.
  • To evaluate suPAR as a potential prognostic biomarker in the context of mild induced hypothermia post-CA.

Main Methods:

  • suPAR levels were measured at 6, 36, and 72 hours post-CA in patients treated with hypothermia.
  • Survival at 6 months was analyzed in relation to suPAR levels.
  • Receiver operating characteristic (ROC) curve analyses were performed to determine prognostic accuracy.
  • Correlation between time to return of spontaneous circulation (ROSC) and suPAR levels was assessed.

Main Results:

  • Sixty percent (33/55) of patients survived for 6 months.
  • Nonsurvivors had significantly higher suPAR levels at 6 and 36 hours compared to survivors (p=0.006 and p=0.034).
  • suPAR levels increased significantly from 6 to 72 hours post-CA (p<0.0001).
  • Time to ROSC positively correlated with suPAR levels at 6 hours (p=0.003).
  • ROC analysis yielded an area under the curve (AUC) of 0.76 at 6 hours, and 0.84 in the cardiac-cause subgroup.

Conclusions:

  • Elevated suPAR levels at 6 and 36 hours post-CA were associated with non-survival.
  • The significant overlap in suPAR levels between survivors and nonsurvivors limits its definitive prognostic value.
  • A consistent increase in suPAR levels was observed during the initial 72 hours following CA.